Year-end Sale % OFF 
Abstract
Brincidofovir (CMX001, BCV) is a broad-spectrum oral antiviral in Phase 3 development for prevention of CMV in hematopoietic cell transplantation. BCV is converted intracellularly to cidofovir diphosphate which acts as an alternative substrate inhibitor for the CMV viral DNA polymerase (UL54, pol). The combination activity and resistance profile of BCV was evaluated in vitro and in two completed clinical trials; Study 201enrolled CMV antiviral naïve subjects and Study 350 enrolled antiviral therapy experienced patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
